Arcus Biosciences, Inc.
https://www.arcusbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Arcus Biosciences, Inc.
Third Time Is Not A Charm: KEYLYNK-006 Is Latest Keytruda/Lynparza Study To Fail
Merck said the Phase III study of the combination in non-small cell lung cancer did not meet its dual primary endpoint of overall survival and progression-free survival.
Arcus And Gilead Make GI Cancers The Focus Of Their TIGIT Hopes
Gilead ups its investment in its TIGIT partner, as the firms pivot to a less crowded market opportunity in upper GI cancers.
Ups And Downs Of Anti-TIGIT Development
Once heralded with optimism, the class of anti-TIGIT molecules has since fallen out of favor, plagued by a succession of disappointing findings.
Gilead Increases Investment In Arcus; Firms Abandon Chemo-Free Combo Study
With a $320m equity investment, Gilead will now own 33% of partner Arcus, which it said reinforces its optimism around the anti-TIGIT class for oncology.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice